Insulet Corporation ( PODD Quick Quote PODD - Free Report) announced fourth-quarter 2020 loss per share of 26 cents against the year-ago earnings of 8 cents per share. Moreover, the reported loss per share were wider than the Zacks Consensus Estimate of a loss of 6 cents per share.
Full-year earnings per share (“EPS”) were 10 cents, reflecting a 47.4% decrease from the year-ago period. Again, the metric lagged the Zacks Consensus Estimate by 68.8%.
Revenues in the fourth quarter totaled $246.1 million, beating the Zacks Consensus Estimate by 6.3%. Moreover, the top line jumped 17.5% from the year-ago number (up 15.3% at constant exchange rate or CER). Notably, the quarterly revenues exceeded the company’s previous expectations of growth of 7-11% at CER.
The robust top-line performance was driven by the company’s growing customer base, increased Omnipod DASH adoption and the continued mix benefit with the shift into the pharmacy channel.
Full-year revenues were $904.4 million, reflecting a 22.5% uptick from the year-ago period (up 21.9% at CER). Again, the metric surpassed the Zacks Consensus Estimate by 1.6%. The full-year revenues exceeded the company’s previous expectations of growth of 20-21% at CER.
Segment in Detail
Insulet delivered fourth-quarter total Omnipod revenues of $231.1 million, reflecting an increase of 20.1% year over year (up 17.6% at CER).
International Omnipod revenues of $81.9 million were up 24.5% (up 17.5% at CER). The revenue uptick included benefits from better-than-expected new-customer starts.
U.S. Omnipod revenues grew 17.8% year over year to $149.2 million.
The Drug Delivery business revenues totaled $15 million, down 11.2% year over year, primarily due to production timing. However, it was ahead of the company’s expectation by $1 million for the fourth quarter.
Gross profit in the reported quarter was $161.1 million, up 20.1% from the prior-year quarter. Gross margin of 65.5% expanded 142 basis points (bps). According to the company, this included an approximate 40 bps adverse impact due to COVID-19-related safety and mitigation costs.
Meanwhile, selling, general & administrative expenses rose 61.6% to $130.1 million. Research and development expenses went up 8.2% year over year to $38.3 million. Operating loss totaled $7.3 million compared with the prior-year quarter’s operating profit of $18.2 million.
Insulet has issued its financial outlook for first-quarter and full-year 2021.
Overall, for the year, total revenues are expected to grow in the band of 17-22% on a reported basis (15-20% at CER). The Zacks Consensus Estimate for total revenues is pegged at $1.03 billion.
Total Omnipod revenues are likely to grow by 19-24% on a reported basis (17-21% at CER). However, Drug Delivery revenues are expected to be within the range of a fall by 11% and a growth of 4%.
For the first quarter of 2021, Insulet projects revenue growth of 24-28% on a reported basis (20-24% at CER). The Zacks Consensus Estimate for total revenues is pegged at $228.9 million.
Total Omnipod revenues are likely to grow by 20-23% on a reported basis (16-19% at CER). Further, Drug Delivery revenues are expected to surge by 120-140% (representing a range of $18 million to $20 million).
Insulet exited the fourth quarter on a strong note with better-than-expected revenues, thanks to year-over-year improvement in the same on the solid uptake of the Omnipod system, both in the United States and international markets. This stupendous growth amid the crisis was primarily due to record revenue growth in total Omnipod product line along with growth in other segments. The momentum of Omnipod DASH is encouraging, based on the solid uptake in geographies in which it has been launched. The completion of the full international commercial launch of Omnipod DASH looks impressive. The company’s plans of geographical expansion buoy optimism. Gross margin expansion is encouraging as well.
However, the rising expenses and operating loss creating a huge bottom-line pressure, and in turn resulting in net loss for the quarter, is concerning.
Zacks Rank and Stocks to Consider
Insulet currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are
Abbott Laboratories ( ABT Quick Quote ABT - Free Report) , Hologic, Inc. ( HOLX Quick Quote HOLX - Free Report) and IDEXX Laboratories, Inc. ( IDXX Quick Quote IDXX - Free Report) .
Abbott reported fourth-quarter 2020 adjusted EPS of $1.45, which surpassed the Zacks Consensus Estimate by 6.6%. Fourth-quarter worldwide sales of $10.7 billion outpaced the consensus mark by 7.9%. The company currently carries a Zacks Rank #2 (Buy). You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hologic reported first-quarter fiscal 2021 adjusted EPS of $2.86, beating the Zacks Consensus Estimate by 33.6%. The company currently carries a Zacks Rank #2.
IDEXX reported fourth-quarter 2020 adjusted EPS of $2.01 which surpassed the Zacks Consensus Estimate by 40.6%. Revenues of $720.9 million beat the consensus mark by 5.8%. The company currently carries a Zacks Rank #2.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>